Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05929651
Other study ID # MEQ00086
Secondary ID U1111-1277-6838
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 7, 2023
Est. completion date September 17, 2024

Study information

Verified date May 2024
Source Sanofi
Contact Trial Transparency email recommended (Toll free number for US &
Phone 800-633-1610
Email Contact-US@sanofi.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the immunogenicity and safety of a single dose of MenQuadfi® administered as a booster vaccine in toddlers 12 - 23 months of age in Argentina who had been primed with at least 1 dose of the quadrivalent meningococcal conjugate vaccines Nimenrix® or Menveo® during infancy to protect against invasive meningococcal disease (IMD). Participants will receive a single dose of MenQuadfi® at Visit 1. Participants will provide 2 blood samples, one at D01 (Visit 1) pre-vaccination and another at D31 (Visit 2) post-vaccination for the immunogenicity assessments. Study will include 2 visits at D01 (Visit 1) and at D31 (Visit 2), and 1 Telephone call (TC) for safety follow-up at D09 post-study vaccination.


Description:

Study duration is approximately 30 days (+14 days) per participant


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date September 17, 2024
Est. primary completion date September 17, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 23 Months
Eligibility Inclusion Criteria: - Aged 12 to 23 months on the day of inclusion - Participants who are healthy as determined by medical evaluation including medical history, physical examination, and judgement of the Investigator - Received at least one priming dose of licensed Nimenrix® or Menveo® vaccine during infancy before 12 months of age with an interval of at least 2 months between the last vaccination with Nimenrix® or Menveo® and the MenQuadfi® booster dose Exclusion Criteria: - Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) - History of meningococcal infection, confirmed either clinically, serologically, or microbiologically - At high risk for meningococcal infection during the study (specifically but not limited to participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease) - Personal history of Guillain-Barré syndrome - Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid containing vaccine - Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances - Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature = 38.0°C [= 100.4°F]) on the day of study intervention administration. Prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided - Receipt of any vaccine (including COVID-19 vaccines) in the 4 weeks preceding the study intervention administration or planned receipt of any vaccine (including COVID-19 vaccines) in the 4 weeks following the study intervention administration except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after the study intervention. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines. - Previous vaccination with a Meningococcal C vaccine or Meningococcal B (MenB) vaccine - Receipt of immunoglobulins, blood or blood-derived products in the past 3 months - Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
MenACYW conjugate vaccine
Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection

Locations

Country Name City State
Argentina Investigational Site Number : 0320002 Buenos Aires Ciudad De Buenos Aires
Argentina Investigational Site Number : 0320001 Ciudad Autonoma Buenos Aires

Sponsors (1)

Lead Sponsor Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary hSBA antibody titers = 1:8 against meningococcal serogroups A, C, Y, and W % of participants achieving antibody titers measured by human complement (hSBA) = predefined threshold of 1:8 Day 31 (+14 days) after booster vaccination
Primary Number of participants with immediate adverse events (AEs) Unsolicited systemic AEs that occur within 30 minutes after vaccination Within 30 minutes after vaccination
Primary Number of participants with solicited injection site reactions or systemic reactions Pre-defined solicited injection site reactions and systemic reactions that are pre-listed in the diary cards and CRF Within 7 days after booster vaccination
Primary Number of participants with unsolicited AEs AEs other than solicited reactions From Day 01 to Day 31 (+14 days) after booster vaccination
Primary Number of participants with serious adverse events (SAEs) SAEs (including adverse events of special interest [AESIs]) reported throughout the study From Day 01 to Day 31 (+14 days) after booster vaccination
Primary hSBA antibody titers against meningococcal serogroups A, C, Y, and W Antibody titers are measured by hSBA and summarized as geometric mean titers (GMTs) Day 01 and Day 31 (+14 days) after booster vaccination
Primary hSBA antibody titers = several pre-defined thresholds against meningococcal serogroups A, C, Y, and W Antibody titers are measured by hSBA and summarized as % of participants achieving antibody titers = predefined thresholds Day 01 and Day 31 (+14 days) after booster vaccination
Primary Percentage of Participants who achieved =4-fold rise in antibody titers over baseline measured by hSBA Day 01 and Day 31 (+14 days) after booster vaccination
Primary hSBA meningococcal serogroups A, C, Y, and W vaccine seroresponse Vaccine seroresponse, defined as follows: For a participant with a pre-vaccination titer < 1:8, a post vaccination titer = 1:16 and for a participant with a pre-vaccination titer = 1:8, a post vaccination titer at least 4-fold greater that the pre vaccination titer Day 01 and Day 31 (+14 days) after booster vaccination
Primary Anti-tetanus antibody concentrations Day 01 and Day 31 (+14 days) after booster vaccination
Secondary Rabbit complement (rSBA) antibody titers against meningococcal serogroups A, C, Y, and W Day 01 and Day 31 (+14 days) after booster vaccination
Secondary rSBA antibody titers = several pre-defined thresholds against meningococcal serogroups A, C, Y, and W Day 01 and Day 31 (+14 days) after booster vaccination
Secondary Percentage of Participants who achieved =4-fold rise in antibody titers over baseline measured by rSBA Day 01 and Day 31 (+14 days) after booster vaccination
Secondary rSBA meningococcal serogroups A, C, Y, and W vaccine seroresponse Vaccine seroresponse defined as follows: For a participant with a pre-vaccination titer < 1:8, a post vaccination titer = 1:32 and for a participant with a pre-vaccination titer = 1:8, a post vaccination titer at least 4-fold greater that the pre vaccination titer Day 01 and Day 31 (+14 days) after booster vaccination
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1
Not yet recruiting NCT06236009 - A First-In-Human Study of TAK-004 in Healthy Adults Phase 1